(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
What's an atmospheric river? AP explains the weather phenomenon - 2Robert Irwin on winning 'Dancing With the Stars' 10 years after sister Bindi: 'This was everything I dreamed it would be and so much more'
- 3Whale stranded off Germany for days found stuck again
- 4Exploring Being a parent: A Survey of \Bits of knowledge and Guidance for Guardians\ Nurturing Book
- 5Heartfelt Objections to Visit with Your Adored One
- Syrian army says recent drone attacks targeted its bases near Iraq, most shot down
- 15 Outrageous Cosplay Outfits That Will Blow You Away
- Find the Lively Food Markets of South America
- The Main 20 Gaming Control center Ever
- Eating Brie, Gouda, cheddar may lower dementia risk, new study says
- Horror and fear in West Bank as Israel approves hanging Palestinians convicted of murdering Israelis
- Believe Should Unwind? Look at These Scaled down Games
- 8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- My Dad Can't Travel Like He Used to, but Slowing Down Doesn't Mean Stopping
